Ｌａｍｉｖｕｄｉｎｅ耐性ウイルスに対してＥｎｔｅｃａｖｉｒを投与したＢ型慢性肝炎例から検出された新たなＥｎｔｅｃａｖｉｒ耐性ウイルス

DOI Web Site 被引用文献1件 参考文献3件

書誌事項

タイトル別名
  • A novel entecavir-resistant virus with patient of lamivudine-resistant hepatitis B virus mutant
公開日
2005
DOI
  • 10.2957/kanzo.46.523
公開者
一般社団法人　日本肝臓学会

この論文をさがす

説明

Entecavir (ETV) exhibits potent antiviral activity in patients chronically infected with wild-type or lamivudine-resistant hepatitis B virus (HBV). Among the patients treated in phase II ETV clinical trials, one patient for whom previous therapies had failed exhibited virologic breakthrough while on ETV. Isolates from this patient were analyzed genotypically for emergent substitutions in HBV reverse transcriptase (RT). After 135 weeks of lamivudine therapy, patient received 0.5 mg of ETV for 52 weeks followed by 1.0 mg of ETV continuously. Viral rebound occurred at 84 weeks after ETV was started. The lamivudine RT substitutions rtH55R, rtL180M and rtM204V were present at study entry, and the additional substitutions rtS202G and rtL269I emerged during ETV treatment.

収録刊行物

  • 肝臓

    肝臓 46 (8), 523-, 2005

    一般社団法人　日本肝臓学会

被引用文献 (1)*注記

もっと見る

参考文献 (3)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ